Search hospitals > Georgia > Augusta
Augusta Oncology Associates PC-D'Antignac
Claim this profileAugusta, Georgia 30901
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
38 reported clinical trials
3 medical researchers
Summary
Augusta Oncology Associates PC-D'Antignac is a medical facility located in Augusta, Georgia. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Augusta Oncology Associates PC-D'Antignac is involved with conducting 38 clinical trials across 40 conditions. There are 3 research doctors associated with this hospital, such as Sharad Ghamande, Vamsi Kota, MD, and Locke J. Bryan.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
2Cancer
HER2 positive
ER positive
ER negative
Top PIs
Sharad GhamandeAugusta University Medical Center1 year of reported clinical research
Expert in Cancer
Expert in Breast Cancer
68 reported clinical trials
145 drugs studied
Vamsi Kota, MDAugusta University Medical Center3 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
8 reported clinical trials
37 drugs studied
Locke J. BryanAugusta University Medical Center5 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
7 reported clinical trials
19 drugs studied
Clinical Trials running at Augusta Oncology Associates PC-D'Antignac
Breast Cancer
Colorectal Cancer
Recurrence
Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Augusta Oncology Associates PC-D'Antignac?
Augusta Oncology Associates PC-D'Antignac is a medical facility located in Augusta, Georgia. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Augusta Oncology Associates PC-D'Antignac is involved with conducting 38 clinical trials across 40 conditions. There are 3 research doctors associated with this hospital, such as Sharad Ghamande, Vamsi Kota, MD, and Locke J. Bryan.